Details of the Drug

General Information of Drug (ID: DMN4CV5)

Drug Name
Calcidiol
Synonyms
Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
Indication
Disease Entry ICD 11 Status REF
Vitamin D deficiency 5B57 Approved [1], [2]
Therapeutic Class
Vitamins
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 400.6
Topological Polar Surface Area (xlogp) 6.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C27H44O2
IUPAC Name
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
Canonical SMILES
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
InChI
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
InChIKey
JWUBBDSIWDLEOM-DTOXIADCSA-N
Cross-matching ID
PubChem CID
5283731
ChEBI ID
CHEBI:17933
CAS Number
19356-17-3
DrugBank ID
DB00146
TTD ID
D02VPX
INTEDE ID
DR0259
ACDINA ID
D00089

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin D3 receptor (VDR) TTK59TV VDR_HUMAN Antagonist [3], [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Vitamin D(3) 24-hydroxylase (CYP24A1) DEFI12S CP24A_HUMAN Substrate [5]
Calcidiol 1-monooxygenase (CYP27B1) DE3FYEM CP27B_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Vitamin D deficiency
ICD Disease Classification 5B57
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vitamin D3 receptor (VDR) DTT VDR 1.69E-02 -0.23 -0.66
Vitamin D(3) 24-hydroxylase (CYP24A1) DME CYP24A1 7.29E-01 1.85E-01 9.48E-02
Calcidiol 1-monooxygenase (CYP27B1) DME CYP27B1 8.48E-02 -6.84E-01 -9.36E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Calcidiol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Magnesium Sulfate DMVEK07 Moderate Increased risk of hypermagnesemia by the combination of Calcidiol and Magnesium Sulfate. Acute pain [MG31] [17]
Butalbital DM9J04X Moderate Increased metabolism of Calcidiol caused by Butalbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [17]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Calcidiol caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [17]
Secobarbital DM14RF5 Moderate Increased metabolism of Calcidiol caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [17]
Primidone DM0WX6I Moderate Increased metabolism of Calcidiol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Felbamate DM1V5ZS Moderate Increased metabolism of Calcidiol caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Calcidiol caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Phenytoin DMNOKBV Moderate Increased metabolism of Calcidiol caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Calcidiol caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Rufinamide DMWE60C Moderate Increased metabolism of Calcidiol caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Phenobarbital DMXZOCG Moderate Increased metabolism of Calcidiol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Carbamazepine DMZOLBI Moderate Increased metabolism of Calcidiol caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Isoniazid DM5JVS3 Moderate Increased metabolism of Calcidiol caused by Isoniazid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Rifampin DMA8J1G Moderate Increased metabolism of Calcidiol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Rifapentine DMCHV4I Moderate Increased metabolism of Calcidiol caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Amobarbital DM0GQ8N Moderate Increased metabolism of Calcidiol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Butabarbital DMC5AST Moderate Increased metabolism of Calcidiol caused by Butabarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Pentobarbital DMFNH7L Moderate Increased metabolism of Calcidiol caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Rifabutin DM1YBHK Moderate Increased metabolism of Calcidiol caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [17]
Orlistat DMRJSP8 Minor Decreased absorption of Calcidiol caused by Orlistat. Obesity [5B80-5B81] [18]
⏷ Show the Full List of 20 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Butylated hydroxytoluene E00336 31404 Antioxidant
FD&C blue no. 1 E00263 19700 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Calcifediol 0.03 mg capsule 0.03 mg 24 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6921).
2 Drug Information of Carbetocin from nextbio research in illumina. 2015.
3 Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
4 Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S.
5 Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res. 2006 Apr 6;7:60.
6 Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99.
7 The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014 May;14(5):342-57.
8 Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
9 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
10 Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
11 Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
12 In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
13 [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
14 New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
15 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
16 Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73.
17 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
18 Product Information. Xenical (orlistat). Roche Laboratories, Nutley, NJ.